Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)

URN to cite this document:: urn:nbn:de:bvb:355-epub-522813
DOI to cite this document:: 10.5283/epub.52281

Hassel, Jessica C. ; Schank, Timo E. ; Smetak, Heiko ; Mühlbauer, Jasmin ; Salzmann, Martin ; Machiraju, Devayani ; Menzer, Christian ; Lang, Kristin ; König, Laila ; Haefner, Matthias F. ; Hülsmeyer, Ingrid ; Kohler, Christian

; Spang, Rainer

; Enk, Alexander ; Debus, Jürgen ; Beckhove, Philipp

Preview

License: Creative Commons Attribution Non-commercial 4.0
PDF - Published Version
(4MB)

Date of publication of this fulltext: 16 May 2022 04:42

Alternative links to fulltext:Pubmed DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

In patients with melanoma brain metastases (MBM), a combination of radiotherapy (RT) with immune checkpoint inhibitors (ICI) is routinely used. However, the best sequence of radio-immunotherapy (RIT) remains unclear. In an exploratory phase 2 trial, MBM patients received RT (stereotactic or whole-brain radiotherapy depending on the number of MBM) combined with ipilimumab (ipi) +/- nivolumab ...